Optimizing the timing of JAK1 inhibition preserves the anti-tumor efficacy of radioimmunotherapy in lung cancer by preventing T cell exhaustion
{{output}}
JAK1 inhibitors are widely used in hematologic malignancies and autoimmune diseases, their potential in combination with immunotherapy for solid tumors such as lung cancer is increasingly being recognized. The combination of radiotherapy and immunotherapy (rad... ...
